Nicotinamide Riboside for Kidney Disease

This trial aims to determine if nicotinamide riboside, a supplement, can reduce the risk of heart disease in individuals with chronic kidney disease (CKD). The study will examine whether this supplement can lower artery stiffness and blood pressure, both linked to heart issues. Participants will take either the supplement or a placebo for three months. The trial suits those diagnosed with stage III or IV CKD who have stable blood pressure and have maintained a steady weight for the past three months. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

The trial information does not specify if you need to stop taking your current medications. However, if you are taking immunosuppressant agents or long-term oral glucocorticoids, you may not be eligible to participate.

Research has shown that nicotinamide riboside, the treatment being tested, is generally safe. In studies, participants taking nicotinamide riboside did not experience significant side effects compared to those taking a placebo, which is a harmless pill. For example, one study found no major differences in negative effects between the groups. Additionally, nicotinamide riboside has received GRAS status, meaning "generally recognized as safe," indicating that experts consider it safe to consume based on current evidence. Even at higher doses, such as 3000 mg daily, nicotinamide riboside has proven to be safe. In summary, existing research supports that nicotinamide riboside is well-tolerated and has a good safety profile.¹²³⁴⁵

Most treatments for kidney disease focus on managing symptoms or slowing progression with medications like ACE inhibitors, ARBs, and diuretics. But Nicotinamide Riboside works differently, targeting cellular health by boosting levels of NAD+, a molecule crucial for energy metabolism and cellular repair. Researchers are excited about Nicotinamide Riboside because it represents a novel approach by potentially enhancing the body's natural repair mechanisms, which might improve kidney function more effectively than current options. Additionally, its oral administration makes it an easy and non-invasive treatment option for patients.

Research has shown that nicotinamide riboside, which participants in this trial may receive, can effectively increase NAD+ levels in the body. NAD+ is an important molecule that helps keep cells healthy and functioning properly. Studies have found that increasing NAD+ can reduce damage caused by free radicals and lower inflammation. In people with high blood pressure, nicotinamide riboside has been shown to make arteries less stiff and lower blood pressure. Animal studies suggest that nicotinamide riboside can protect the kidneys and reduce kidney damage. These findings support its potential to improve heart and kidney health, especially in those with chronic kidney disease.¹⁶⁷⁸⁹